ACHN - ACHN Stock Climbs After Achillion Pharmaceuticals' Trial Fills Up

ACHN stock is one of the top performing biotech stocks so far in 2019. Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) are up over 115% since early January amid several key clinical updates.

In Wednesday’s session, Achillion Pharmaceuticals’ stock moved up by 4.78%, to close at $3.29, following an announcement that it reached threshold enrollment in vital Phase 2 clinical studies.

The two Phase 2 clinical studies will evaluate the safety and efficacy of the ACH-4471 developmental treatment targeting a rare kidney illness called C3 glomerulopathy (C3G). The biopharma announced that it reached its enrollment capacity ...